Jon Magnus Tangen

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

Eva Hellström‐Lindberg, Nina Gulbrandsen, Greger Lindberg et al. · British Journal of Haematology · 2003 · 454 citations · Full text

Hematological Malignancy, Immunohematology, Laboratory Hematology +15

Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group

Stig Lenhoff, Martin Hjorth, Jan Westin et al. · British Journal of Haematology · 2006 · 74 citations · Full text

Hematological Malignancy, Intensive Therapy, Oncology +13

Hematopoietic engraftment of dimethyl sulfoxide–depleted autologous peripheral blood progenitor cells

Çiğdem Akalın Akkök, Mette R. Holte, Jon Magnus Tangen et al. · Transfusion · 2009 · 60 citations

Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

Michael Grövdal, Mohsen Karimi, Rasheed Khan et al. · British Journal of Haematology · 2010 · 59 citations · Full text

Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome

Michael Grövdal, Rasheed Khan, Anni Aggerholm et al. · Clinical Cancer Research · 2007 · 55 citations · Full text